BLAINJECTIONINJECTABLEPriority Review
Approved
Aug 2011
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
ADCETRIS (brentuximab vedotin) by Pfizer is cd30-directed antibody interactions [moa]. First approved in 2011.
Drug data last refreshed 42m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADCETRIS is a CD30-directed antibody-drug conjugate (ADC) approved in 2011 for hematologic malignancies including Hodgkin lymphoma and systemic anaphylactic lymphoma. It works by binding to CD30 on tumor cells and delivering cytotoxic payload (monomethyl auristatin E) intracellularly. This pioneering ADC mechanism combines antibody specificity with potent chemotherapy targeting.
$0.003BPart D
PeakProduct is at peak lifecycle stage with modest Part D utilization (81 claims, 2023), indicating mature market penetration with smaller commercial team requirements.
Mechanism of Action
CD30-directed Antibody Interactions
Pharmacologic Class:
CD30-directed Immunoconjugate
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)
Started Jul 2026
46 enrolled
Cutaneous T-Cell Lymphoma/Mycosis FungoidesPrimary Cutaneous Anaplastic Large Cell Lymphoma
Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain
Started Feb 2026
100 enrolled
CD30-Positive Peripheral T-Cell Lymphoma
A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India
Started Aug 2024
124 enrolled
Hodgkin Lymphoma
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
Started Feb 2024
3 enrolled
Diffuse Cutaneous Systemic Sclerosis
A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin
Started Feb 2024
26 enrolled
T-Cell Lymphoma
Worked on ADCETRIS at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.